Recent cardiovascular outcome trials (CVOTs) have demonstrated that SGLT2 inhibitors improve cardiovascular and renal outcomes in patients, both with and without type 2 diabetes mellitus (TD2M). Here, SLC5A2 is linked to type 2 diabetes mellitus.